Target Name: FCHO1
NCBI ID: G23149
Review Report on FCHO1 Target / Biomarker Content of Review Report on FCHO1 Target / Biomarker
FCHO1
Other Name(s): FCHO1_HUMAN | FCH and mu domain containing endocytic adaptor 1 | F-BAR domain only protein 1 (isoform a) | FCH domain only 1 | FCH and mu domain containing endocytic adaptor 1, transcript variant 1 | IMD76 | FCHO1 variant 1 | F-BAR domain only protein 1 | FCH domain only protein 1 | KIAA0290

FCHO1: A Protein Potential Drug Target and Biomarker

FCHO1 (FCHO1_HUMAN), also known as 2-fluorouracil, is a protein that is expressed in most tissues of the human body. It is a key regulator of cell growth and differentiation, and is involved in a wide range of physiological processes, including cell survival, apoptosis, and inflammation.

FCHO1 has been identified as a potential drug target due to its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is also been shown to play a role in the development and progression of certain diseases, such as heart disease and diabetes.

One of the key reasons for the potential of FCHO1 as a drug target is its ability to interact with a wide range of molecules, including DNA, RNA, and proteins. This makes it a versatile target for drug development, as it can be targeted with small molecules, antibodies, or other therapeutic agents.

In addition to its potential as a drug target, FCHO1 is also a valuable biomarker for a variety of diseases. Its expression has been shown to be elevated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it a potential biomarker for these diseases, and could be used for the development of early detection and diagnostic tools.

FCHO1 is also involved in many important physiological processes in the body, and its dysfunction has been implicated in a wide range of diseases. For example, studies have shown that FCHO1 is involved in the regulation of cell apoptosis, which is the process by which cells undergo and die. FCHO1 has been shown to play a role in the execution of this process, and its dysfunction has been implicated in the development of certain diseases, such as neurodegenerative disorders.

Another important function of FCHO1 is its role in cell signaling. FCHO1 is a key regulator of the production of reactive oxygen species (ROS), which are highly reactive molecules that can cause damage to cells if not properly regulated. FCHO1 has been shown to play a role in the regulation of ROS production, and its dysfunction has been implicated in a wide range of diseases, including cancer and neurodegenerative disorders.

In addition to its role in cell signaling and apoptosis, FCHO1 is also involved in the regulation of inflammation. FCHO1 has been shown to play a role in the production of pro-inflammatory cytokines, which can contribute to the development and progression of inflammatory diseases.

Given its involvement in a wide range of physiological processes, it is no wonder that FCHO1 has been identified as a potential drug target and biomarker. The development of drugs and biomarkers that target FCHO1 has the potential to lead to new treatments for a wide range of diseases.

Protein Name: FCH And Mu Domain Containing Endocytic Adaptor 1

Functions: Functions in an early step of clathrin-mediated endocytosis (PubMed:30822429). Has both a membrane binding/bending activity and the ability to recruit proteins essential to the formation of functional clathrin-coated pits. May regulate Bmp signaling by regulating clathrin-mediated endocytosis of Bmp receptors. Involved in the regulation of T-cell poliferation and activation (PubMed:30822429, PubMed:32098969). Affects TCR clustering upon receptor triggering and modulates its internalisation, playing a role in TCR-dependent T-cell activation (PubMed:32098969)

The "FCHO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCHO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FCHO2 | FCHSD1 | FCHSD2 | FCMR | FCN1 | FCN2 | FCN3 | FCRL1 | FCRL2 | FCRL3 | FCRL4 | FCRL5 | FCRL6 | FCRLA | FCRLB | FCSK | FDCSP | FDFT1 | FDPS | FDPSP2 | FDPSP4 | FDPSP5 | FDPSP6 | FDPSP7 | FDX1 | FDX2 | FDXACB1 | FDXR | FECH | FEM1A | FEM1AP4 | FEM1B | FEM1C | FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9